Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2022.13325

OL-24-01-13325

Review

Metformin: A promising drug for human cancers

Hongnian

1 * Huang

Dan

2 * Zhou

Hong

1 Sima

Xueqin

3 Wu

Zhe

3 Sun

Yanling

3 Wang

Long

4 Ruan

Ying

5 Wu

Qian

6 Wu

Feng

7 She

Tonghui

8 Chu

Ying

2 Huang

Qizhi

9 Ning

Zhifeng

1 Zhang

Hao

1Department of Human Anatomy, Basic Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China 2Department of Burn and Plastic Surgery, Enshi State Central Hospital, Enshi, Hubei 445099, P.R. China 3Department of Histology and Embryology, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China 4Department of Microbiology, Basic Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China 5Department of Dermatology, Clinical Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China 6Nursing School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China 7Stomatology and Optometry School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China 8Department of Pathology, Basic Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China 9Department of Clinical Lab, Second Affiliated Hospital, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China 10Institute of Precision Cancer Medicine and Pathology, Department of Pathology, Jinan University Medical College, Guangzhou, Guangdong 510630, P.R. China

Correspondence to: Mr. Qizhi Huang, Department of Clinical Lab, Second Affiliated Hospital, Hubei University of Science and Technology, 58 Chahua Road, Xianning, Hubei 437100, P.R. China, E-mail: huangqzhome@126.com Dr Ying Chu, Department of Burn and Plastic Surgery, Enshi State Central Hospital, 158 Wuyang Avenue, Enshi, Hubei 445099, P.R. China, E-mail: 12977698@qq.com *

Contributed equally

07 2022

12 05 2022

24 1

204

27102021 12042022

2022

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Small-molecule chemical drugs are of great significance for tumor-targeted and individualized therapies. However, the development of new small-molecule drugs, from basic experimental research and clinical trials to final application in clinical practice, is a long process that has a high cost. It takes at least 5 years for most drugs to be developed in the laboratory to prove their effectiveness and safety. Compared with the development of new drugs, repurposing traditional non-tumor drugs can be a shortcut. Metformin is a good model for a new use of an old drug. In recent years, the antitumor efficacy of metformin has attracted much attention. Epidemiological data and in vivo, and in vitro experiments have shown that metformin can reduce the incidence of cancer in patients with diabetes and has a strong antagonistic effect on metabolism-related tumors. Recent studies have shown that metformin can induce autophagy in esophageal cancer cells, mainly by inhibiting inflammatory signaling pathways. In recent years, studies have shown that the antitumor functions and mechanisms of metformin are multifaceted. The present study aims to review the application of metformin in tumor prevention and treatment.

metformin tumor prevention treatment esophageal cancer repurpose

Xianning high-level personnel project

Hubei University of Science and Technology developing project

2019-21GP04

Hubei University of Science and Technology developing

2019-20X018

pharmacy project

2019-20YZ03

WZ, Hubei University of Science and Technology

BK1431

Hubei Department of Education direction project

B201771

WHN, National Natural Science Foundation of China Youth Science Foundation project

81902937

This study was supported by the following grants: Xianning high-level personnel project (grant no. 3) and Hubei University of Science and Technology developing project (grant no. 2019-21GP04) for NZF, Hubei University of Science and Technology developing (grant no. 2019-20X018) and pharmacy project (grant no. 2019-20YZ03) for WZ, Hubei University of Science and Technology doctor initiation project (grant no. BK1431) and Hubei Department of Education direction project (grant no. B201771) for WHN, National Natural Science Foundation of China Youth Science Foundation project (grant no. 81902937) for SYL.

1. Introduction

In the field of antitumor therapy, small-molecule drug therapy is a targeted form of treatment with high specificity and few adverse reactions. Small-molecule drugs are called ‘biological missiles’ and are gradually becoming a hot spot in research, development and clinical application. Repurposing old small-molecule drugs is an active focus of research. Metformin is a typical ‘old medicine with new uses’. Metformin is a 1,1-dimethylbiguanide hydrochloride isolated from the legume Galega officinalis. It was first reported in 1957 as a hypoglycemic drug (1). Studies have found that metformin has weight loss, anti-aging, and anti-cardiovascular effects (2). In recent years, studies have reported an antitumoral effect of the drug, which has been confirmed in various malignant tumor cells such as liver (3), ovarian (4) and lung cancer cells. The present study summarizes knowledge on the anti-tumoral effects of metformin and its mechanism in order to provide evidence for the repurposing of this drug for tumor treatment.

<sec> <title>Antitumoral advantages of small molecule drugs

Biomacromolecular drugs are considered one of the most promising fields in drug development in this century. Common biomacromolecular antitumor drugs include monoclonal antibodies, recombinant protein drugs and vaccines (5). These biomacromolecular drugs have some shortcomings in clinical use: i) Lack of selectivity for targeted lesion tissues in contrast to normal tissues, which may cause serious adverse reactions; ii) most drugs cannot enter cells to exert an antitumoral effect and iii) their mechanism of action on tissues, organs, cells and molecules within the body is frequently uncertain, therefore it is difficult to evaluate their efficacy (6). These factors lead to unsatisfactory clinical therapeutic effects of biomacromolecular drugs. By contrast, small-molecule drugs are more popular in the clinics because they may have better therapeutic efficacy and fewer adverse reactions. More importantly, they are relatively inexpensive (7). However, with the widespread application of these drugs, their shortcomings have also became prominent: Ease in development of drug resistance and multiple adverse reactions, resulting in reduced clinical efficacy. For example, gefitinib and erlotinib used in the treatment of non-small cell lung cancer (NSCLC) (8), imatinib in the treatment of chronic myeloid leukemia (8) and gastrointestinal stromal tumors (9) are reported to have several side effects and develop tumor resistance.

Among the numerous strategies available to improve tumor treatment (10), the development of new drugs is worth considering. However, this development requires a large amount of funding, a long testing period and large-scale and multi-center clinical trials. The economic and time costs of new drug research and development are huge, and it is difficult to improve the current status of tumor treatment in the short term. Therefore, exploring the functions and indications of existing non-antitumoral small-molecule drugs to evaluate their potential antitumoral efficacy, and therefore repurposing ‘old drugs’ is an important way to improve the clinical efficacy of antitumoral treatment.

Metformin, the chemical structure of which is shown in Fig. 1, is the first-line drug used clinically for type 2 diabetes. In recent years, it was discovered that the drug has antitumoral effects, which is a typical form of repurposing (11). In addition to metformin, there are a number of small-molecule drugs that have regained a ‘new life’ in the anti-cancer field, such as aspirin (12), thalidomide (13), statins (14), vitamin D (15) and green tea extract (16).

Metformin bioavailability

The cellular uptake and secretion rate of metformin largely depends on the expression of organic cation transporters and of multidrug and toxin extrusion proteins (17). The organic cation transporter, toxin extrusion protein and plasma membrane monoamine transporter distribute metformin to several tissues, such as the liver, kidneys and small intestine, and also mediate metformin metabolism and secretion. Oral metformin is mainly absorbed through the upper small intestine. Knockout mice for the toxin extrusion protein transporter show a significant reduction in the clearance and distribution of metformin, usually without an effect on tissue distribution or pharmacological effects (10). The bioavailability of oral metformin is 40-60% (18). Metformin uptake is dose-dependent, but saturable (19). In clinical trials, the plasma elimination half-life is ~5-6 h in patients with normal renal function under repeated metformin administration (20). Approximately 90% of oral metformin is secreted through the kidneys within 24 h. However, for patients with advanced cancer and gastrointestinal tumors with poor prognosis, the possibility of reaching high blood concentrations is low (21). In a cell line model, the half-inhibitory concentration (IC₅₀) of metformin is between 5 and 20 mM. In breast cancer cell lines, the IC₅₀ of metformin is increased and apoptosis and cell cycle arrest induced by metformin are decreased at high glucose levels compared with low glucose levels (22). The in vitro activation of cellular AMP-activated protein kinase (AMPK) requires at least 1 mM metformin in numerous cancer cell lines (23). This is equivalent to an intracellular concentration of 131 µM, which is close to the plasma concentration of metformin in mice receiving an intraperitoneal injection of 145 µM. Compared with oral metformin, the intraperitoneal injection can increase the bioavailability of metformin in mice. In particular, the metformin concentration in the blood, liver and kidneys increases, significantly (18). In mouse tumor models, the biodistribution of ¹¹C-metformin administered intravenously shows relatively high tracer uptake in the kidneys and liver, and relatively low tracer uptake in the blood and tumors (24). ¹¹C-metformin-positron emission tomography can be combined with mutation screening of metformin sensitivity-related genes and can be used clinically to identify metformin-sensitive tumors. In a rat model of lipopolysaccharide-induced systemic inflammation, the concentration of metformin varies between different brain regions, with the highest concentration of metformin in the pituitary gland and cerebrospinal fluid (~30 µM).

2. Metformin as an antitumor candidate drug <sec> <title>Multiple functions of metformin

Metformin was originally chemically synthesized in 1929 (25). It was first approved as a clinical drug in 1957 and has since been used to treat diabetes (26). In 1998, metformin was discovered to have a protective effect on the cardiovascular system (27). Since then, other functions of the drug have been discovered (Fig. 2). For example, metformin can be used in the adjuvant treatment of tuberculosis (28), and it is also used in the routine treatment of polycystic ovary syndrome (29). In addition, metformin can delay aging and improve the symptoms of non-alcoholic fatty liver (30), prevent and treat uveitis (31), reduce the prevalence of Parkinson's disease (32) and improve the intestinal flora imbalance in diabetic patients (33). Basic research has shown that metformin inhibits the expression of mammalian target of rapamycin (mTOR) by activating AMPK to improve rheumatoid arthritis (34). Metformin combined with risperidone can significantly improve fasting blood glucose, triglyceride levels, high-density lipoprotein levels, and body mass index in patients with schizophrenia complicated with metabolic syndrome, and effectively reduce the incidence of metabolic syndrome (35).

Antitumoral effects of metformin The basis of the antitumoral effect of metformin

In 1910, Maynard suggested that diabetes is associated with tumors (36). Since then, an increasing number of studies have shown that diabetes can increase the risk of various malignant tumors (37–39). Diabetes and tumors have common risk factors, including age, sex, diet and smoking and their onset is related to the insulin/insulin-like growth factor (IGF) pathway (40). Patients with diabetes are prone to develop tumors. At present, most studies suggest that hyperglycemia, hyperinsulinemia, IGF-1, DNA damage, inflammatory factors and obesity may be involved in the pathological process of diabetes-related tumors (41–43). Adequate blood sugar control is beneficial in reducing the risk of malignant tumors. Obese patients with type 2 diabetes have a higher risk of developing cancer such as liver (44), biliary tract (45), pancreatic (46), colorectal (47), kidney (48), bladder (49), breast (50) and endometrial cancer (51). Insulin resistance leads to unsatisfactory treatment effects in diabetes, and is a chronic, non-specific inflammatory process. Insulin resistance not only leads to an increase in insulin and IGFs, but also promotes mitosis (52), activates the PI3K/AKT cell proliferation signaling pathway, promotes tumor cell growth (53) and aggravates the tumor inflammatory response to promote tumor invasion and metastasis.

Studies have reported that metformin has an effect on tumors of non-obese patients. Metformin can inhibit growth and promote differentiation of ovarian (54), endometrial (55), and breast cancer (56), thereby reducing the risk and mortality of these tumors. Jayalath et al (44) found that metformin reduced the level of serum prostate-specific antigen and delayed the progression of prostate cancer. In addition, metformin increases the sensitivity of patients with colorectal cancer (especially those with diabetes) to radiotherapy and improved the progression-free survival of patients with NSCLC (57). Additionally, metformin inhibits metastasis of malignant gliomas (58).

Epidemiological research on the antitumoral effect of metformin

In recent years, epidemiological data have shown that diabetes increased the risk of a number of tumors. The cancer mortality rate in patients with diabetes is 1.41 times that of patients without diabetes (59). Studies have shown that metformin reduced the incidence of cancer by 30-50%, especially pancreatic cancer (60), hepatocellular carcinoma (61) and colon cancer (62). Febbraro et al (63) conducted a retrospective cohort study on 341 patients with ovarian cancer and found that, the 5-year progression-free survival rate of diabetic patients taking metformin was higher than diabetic patients who did not take metformin and non-diabetic patients., but the 5-year overall survival rates were not significantly different. Xu et al (64) reported that the pathological complete response rate of patients with diabetes and breast cancer taking metformin was 24%, which was higher than that of patients not taking metformin (8%) and also higher than that of patients without diabetes taking metformin (16%), suggesting that metformin may improve the prognosis of breast cancer in patients with diabetes. Wang et al (65) proved through randomized controlled trials that for patients with breast cancer but without diabetes, metformin could improve the prognosis of breast cancer by reducing blood insulin and testosterone levels. Tseng (66) showed that metformin significantly reduced the incidence of prostate cancer in men with type 2 diabetes mellitus. In a follow-up study of patients with newly developed diabetes between 1998 and 2002, as of the end of 2009, the incidence of prostate cancer in patients with diabetes taking metformin was 239.42/100,000 per year, while the incidence of non-users was 737.10/100,000 person-years, and the adjusted risk odds ratio was 0.467 (95% CI, 0.446-0.488). A comparison of the survival of 750 patients with stage 4 NSCLC aged 65-80 years old found that 61% of the patients were already taking metformin when they were diagnosed with lung cancer (67). The median survival time of the metformin group was 5 months, while that of the non-users was 3 months with a statistically significant difference (67). Studies on the risk of thyroid cancer in patients with type 2 diabetes taking metformin have also shown that metformin could reduce the incidence of thyroid cancer (68). The incidence rate of patients taking metformin was 24.09/100,000 person-years, while the incidence rate of those not taking metformin was 87.33/100,000 person-years, with an adjusted risk ratio of 0.683 (95% CI, 0.598-0.780) (68). Other studies have also shown that metformin decreases the risk of esophageal adenocarcinoma (69) and endometrial cancer (70). Bowker et al (71) conducted a five-year follow-up of 10,309 newly-diagnosed patients with type 2 diabetes, and found that the tumor-related mortality of patients taking metformin was significantly lower than that of patients using sulfonylurea-type hypoglycemic drugs or insulin. Another meta-analysis on 13,008 patients with type 2 diabetes and tumors showed that the survival rate of tumor patients using metformin was significantly higher than that of non-users, and cancer-related mortality was significantly lower than that of non-users (72). Metformin is likely to inhibit tumor progression in patients with type 2 diabetes and can reduce the progression risk of patients with tumors and tumor-related mortality, thereby improving patient survival.

Experimental research on metformin antitumoral activity

Emerging evidence has shown that metformin can inhibit the growth of several types of cancer cells in vitro (73–75). At the same time, its antitumoral effect in a mouse tumor model has also been confirmed (76). Huang et al (76) reported that PTEN knockout mice fed with 300 mg/kg/day metformin had delayed tumorigenesis, and that metformin effectively inhibits growth of colon polyps. In addition to inhibiting spontaneous and carcinogen-induced tumors, metformin could inhibit allograft tumors. Phoenix et al (77) implanted tumor cells cultured in a high-sugar and high-insulin environment into mice, and found that the administration of metformin at a dose 40 times higher than the clinical dose effectively reduces the growth rate of tumors. Anisimov et al (78) found that metformin significantly inhibited tumor growth in HER2/neu transgenic mice and increased their average life span. Memmott et al (79) used the tobacco carcinogen NNK to generate an A/J mouse lung cancer model and found that metformin could delay tumorigenesis and reduced tumor burden in mice. It was hypothesized that the antitumoral effect of metformin was related to the downregulation of insulin and IGF-1 receptor. The AKT receptor pathway was also involved. Metformin could indirectly reduce the expression of mTOR (the ‘master factor’ of protein synthesis in cells) in the mouse lung tissue through the AKT pathway, leading to the inhibition of tumor cell growth.

Antitumoral mechanism of metformin The protein kinase (AMPK)/mTOR pathway

AMPK is one of the main regulators of cell energy status and key cellular processes such as lipid and glucose metabolism, cell growth, autophagy and apoptosis. This enzyme maintains mitochondrial homeostasis and is activated when the ratio of AMP or ADP to ATP increases, and compensates for energy loss by upregulating glycolysis (80). Tumors such as breast (81), pancreatic (82) and prostate cancer (83) are related to obesity, which in turn is associated with the AMPK/mTOR metabolic pathway (84). AMPK is the cell's ‘energy receptor’ being activated when energy is lacking and inhibited when energy is excessive. After AMPK is activated, it can regulate multiple pathways, including the mTOR pathway, thus dominating intracellular protein synthesis (84). Most studies have shown that metformin inhibits obesity-related tumors through the AMPK/mTOR pathway (85,86). In this pathway, AMPK activation by metformin requires an interaction between the regulatory factor liver kinase B-1 and inositol polyphosphate multikinase (87). In addition, the lysosomal pathway is essential for metformin to activate AMPK (88). Metformin activates AMPK through phosphorylation, which in turn downregulates the expression of key adipogenic transcription factor sterol regulatory elements combined with transcription factor 1, leading to the downregulation of lipogenic enzymes, such as Fas cell surface death receptors (89). Metformin directly and indirectly activates AMPK. AMPK can block proliferation and metastasis of tumor cells by compromising mTOR. Tumor cells cannot survive because they cannot synthesize proteins normally (90) (Fig. 3).

Metformin does not act only on AMPK to function. Compared with normal cells, cancer cells have a higher ATP demand. Metformin can reversibly inhibit NADH dehydrogenase (mitochondrial complex I) activity of the respiratory chain and exert its role as an inhibitor of oxidative phosphorylation at the molecular level, thereby inhibiting ATP production. Metformin accumulates in the mitochondrial matrix in the presence of a polarized mitochondrial membrane potential. By inhibiting the effective coupling of redox and proton transfer domains, it reversibly inhibits the NADH dehydrogenase (mitochondrial complex I) of the respiratory chain (91), thereby inhibiting ATP production.

Inflammatory pathways and cell death induction

Metformin also has antitumoral effects on tumors of non-obese patients and can cause tumor cell death. Cell death can be divided into programmed and unprogrammed cell death, the latter of which is also known as necrosis. According to the Clarke morphological classification, programmed cell death can be divided into: i) Apoptosis); ii) autophagic cell death and iii) necrosis-like programmed cell death. Feng et al (92) found that metformin inhibited tumors by inducing tumor cell apoptosis and autophagy, in the treatment of esophageal cancer. Metformin-mediated apoptosis of esophageal cancer cells was subtle, and the main mechanism of cell death was autophagy. Additionally, it was found that AMPK was not the only pathway involved in metformin-mediated esophageal cancer cell apoptosis and autophagy.

Several metformin effects do not rely on AMPK mechanisms, these are known as the pleiotropic effect of metformin in tumor treatment (93–95). Biochemical studies have shown that the redox shuttle enzyme mitochondrial glycerol-3-phosphate dehydrogenase (GPDH) was another major target (96). The drug reduced the redox state of mitochondria (in the plasma and liver) and limited the conversion of lactic acid to glycerol and glucose, thereby reducing liver gluconeogenesis. Mitochondrial GPDH was overexpressed in the tumoral thyroid compared with that of normal thyroid tissues. Thyroid cancer cells with high mitochondrial GPDH expression were more susceptible to the inhibitory effects of metformin during proliferation (97). Hexokinase II is attached to the outer mitochondrial membrane and is highly expressed in cancer cells. Cell experiments and molecular simulation studies have shown that metformin inhibited the activity of hexokinase II by occupying the binding site of glucose-6-phosphate, and directly impaired glucose metabolism (98). This induced the dissociation of hexokinase II from mitochondria, leading to the activation of apoptotic signals.

Esophageal cancer was an inflammatory tumor (99). The Stat3 gene product is at the intersection of many cancer and inflammatory signaling pathways (100). Therefore, it was possible that the mechanism of action of metformin in esophageal cancer was related to Stat3. Feng et al (92) showed that the treatment of esophageal cancer by metformin activated the STAT3 pathway, especially the STAT3/Bcl-2/ATG network signaling pathway, promoted apoptosis and autophagy, in which autophagy had a protective effect on the metformin-mediated apoptosis, inducing an inhibition of tumor growth (Fig. 4). The results clarified the target of metformin in the treatment of esophageal cancer, revealed the possibility of combining autophagy inhibitors to enhance the clinical efficacy of metformin, and laid the foundation for the optimal design of esophageal cancer treatment options.

Other antitumoral effects of metformin

Other metformin antitumoral effects were presented in a recent study that reported that metformin had the potential to block or delay all kinds of malignant biological behaviors, such as cell cycle arrest, sensitivity to radiotherapy and chemotherapy, and inhibition of proliferation and differentiation of cancer stem cells (101).

3. Clinical trials on metformin in the treatment of tumors

The short-term randomized clinical trial by Higurashi et al (102) showed that metformin could reduce abnormal colorectal polyps by 40% compared with the control group. Currently, several clinical trials (such as NCT04559308, NCT04387630 and NCT03137186) on cancer treatment with metformin have been initiated. Most ongoing clinical trials are based on the evaluation of changes in biomarkers, including insulin levels, AKT/mTOR signals and Ki67 staining. In addition, the clinical benefit of metformin, which uses response and survival rates as indicators, have also been studied, and retrospective studies have used cancer chemotherapy response and survival time as indicators, proving that metformin has potential clinical benefits (103,104).

Our research group adopted a short-term preoperative metformin neoadjuvant treatment for esophageal squamous cell carcinoma and analyzed the changes in the proliferation and apoptosis indices of cancer tissues of patients with metformin. Preliminary results confirmed that cancer proliferation is inhibited by the short-term administration of metformin before surgery, indicating that the patient can benefit from short-term sustained-release of metformin treatment before surgery (105). The main side effect of metformin in patients is gastrointestinal discomfort. These results provide a theoretical basis for further application of metformin in the treatment of esophageal cancer.

The results of a meta-analysis showed that for patients with type 2 diabetes, the effect on blood sugar control was not sufficient when using metformin alone and that metformin combined with sulfonylurea hypoglycemic agents could improve blood sugar control and reduced cardiovascular disease mortality in patients with type 2 diabetes (106). Recent research has shown that metformin combined with chemotherapy drugs can significantly decrease local recurrence in patients with diabetes and NSCLC (107). In addition, compared with VEGF-A inhibitors alone, metformin combined with VEGF-A inhibitors is more effective in inhibiting tumor growth (108), indicating that the combined application of metformin can be a promising route to increase its antitumoral efficacy.

4. Conclusions

Metformin is a small-molecule drug with multiple pharmacological functions. Although research on metformin as an antitumoral drug is still in its preliminary stage, its potential antitumoral efficacy has made people look forward to studying metformin. Based on current research, it is hypothesized that metformin combined with radiotherapy and chemotherapy can enhance the clinical efficacy against tumors, thereby benefiting patients. Further research on metformin should be carried out on the two following aspects: i) Improvement of the molecular structure and pharmaceutical form of metformin, such as modifying tablets into other pharmaceutical forms to produce targeted drugs to improve efficacy and reduce adverse reactions, or coupling certain active groups to the chemical structure of metformin to increase its specificity and effective concentration; ii) evaluation of the combination of metformin with other drugs to improve efficacy. In both cases, the ultimate goal of researchers is to fully understand and optimize the antitumoral effect of metformin in clinical practice and benefit patients.

Acknowledgements

Not applicable.

Availability of data and materials

Not applicable.

Authors' contributions

HZha, ZN, TS and YC designed the study. HW, DH, HZho, ZW, FW, LW and QW wrote the manuscript. YS, ZN, XS, YR, QH and HZha revised the manuscript. Data authentication is not applicable. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Nasri

Rafieian-Kopaei

Metformin: Current knowledge

J Res Med Sci196586642014

Top

WMC

Kooy

Stehouwer

CDA

Metformin: A narrative review of its potential benefits for cardiovascular disease, cancer and dementia

Pharmaceuticals (Basel)153122022

10.3390/ph15030312

35337110

Kramer

Natarajan

Dai

El-Serag

Kanwal

Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease

Hepatology15322442021

10.1002/hep.32244

Gralewska

Gajek

Marczak

Rogalska

Metformin affects olaparib sensitivity through induction of apoptosis in epithelial ovarian cancer cell lines

Int J Mol Sci22105572021

10.3390/ijms221910557

Tsogas

Majerczyk

Hart

Possible role of metformin as an immune modulator in the tumor microenvironment of ovarian cancer

Int J Mol Sci228672021

10.3390/ijms22020867

Adeyemi

Choonara

Current advances in cell therapeutics: A biomacromolecules application perspective

Expert Opin Drug Deliv121182022

10.1080/17425247.2022.2064844

Liao

Qin

Huang

Zhu

Peng

Han

Liu

Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: A revisited perspective from molecular mechanisms to targeted therapies

J Hematol Oncol15442022

10.1186/s13045-022-01260-0

Marciano

Mehazri

Shpungin

Varvak

Zacksenhaus

Nir

Fer and fert govern mitochondrial susceptibility to metformin and hypoxic stress in colon and lung carcinoma cells

Cells10972021

10.3390/cells10010097

Mohammadi

Arefnezhad

Danaii

Yousefi

New insights into the core Hippo signaling and biological macromolecules interactions in the biology of solid tumors

Biofactors465145302020

10.1002/biof.1634

32445262

Kim

Hwang

Kim

Choi

Gene therapy strategies using engineered stem cells for treating gynecologic and breast cancer patients (Review)

Oncol Rep33210721122015

10.3892/or.2015.3846

25760693

Hotta

Kiura

Ueoka

Tabata

Fujiwara

Kozuki

Okada

Hisamoto

Tanimoto

Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

Lung Cancer462552612004

10.1016/j.lungcan.2004.04.036

15474674

Lankheet

Schaake

Burgers

van Pel

Beijnen

Huitema

ADR

Klomp

NEL Study Group

Concentrations of erlotinib in tumor tissue and plasma in non-small-cell lung cancer patients after neoadjuvant therapy

Clin Lung Cancer163203242015

10.1016/j.cllc.2014.12.012

25682545

Zitvogel

Rusakiewicz

Routy

Ayyoub

Kroemer

Immunological off-target effects of imatinib

Nat Rev Clin Oncol134314462016

10.1038/nrclinonc.2016.41

Joensuu

Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec)

Med Klin (Munich)15(Suppl 1)S28S302002

Cohen

Pop

Icard

Berthet

Venissac

Mouroux

Is there a place for thoracoscopic enucleation of esophageal gastrointestinal stromal tumors?

Thorac Cardiovasc Surg675855882019

10.1055/s-0038-1670662

30267389

Chen

Yang

Tsai

Chen

Chou

Hsiao

Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells

Mol Med Rep23882021

10.3892/mmr.2020.11725

33236135

Zheng

Zhou

Lin

Yao

Progress on the mechanism for aspirin's anti-tumor effects

Curr Drug Targets221051112021

10.2174/1389450121999201013152931

33050859

Pereira

PMR

Mandleywala

Ragupathi

Lewis

Acute statin treatment improves antibody accumulation in EGFR- and PSMA-expressing tumors

Clin Cancer Res26621562292020

10.1158/1078-0432.CCR-20-1960

32998959

Pereira

de Souza Lima

da Silva-Junior

Silva

EDS

de Araújo Júnior

Martins

Alves

JSF

de Santana Oliveira

Ferreira

LDS

de Araújo Costa

ECT

In vitro-in vivo availability of metformin hydrochloride-PLGA nanoparticles in diabetic rats in a periodontal disease experimental model

Pharm Biol59157615842021

10.1080/13880209.2021.2002369

Horas

van Herck

Maier

Maus

Harrasser

Jakob

Weissenberger

Arnholdt

Holzapfel

Rudert

Does vitamin D deficiency predict tumour malignancy in patients with bone tumours? Data from a multi-center cohort analysis

J Bone Oncol251003292020

10.1016/j.jbo.2020.100329

Zeng

Holly

Perks

Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cells

Front Endocrinol (Lausanne)5612014

10.3389/fendo.2014.00061

24847310

Varghese

Samuel

Varghese

Kubatka

Büsselberg

High glucose represses the anti-proliferative and pro-apoptotic effect of metformin in triple negative breast cancer cells

Biomolecules9162019

10.3390/biom9010016

Kawakita

Yang

Kumagai

Takagaki

Kitada

Yoshitomi

Ikeda

Nakamura

Ishigaki

Kanasaki

Koya

Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of mTOR signaling

Mol Cancer Res1961732021

10.1158/1541-7786.MCR-20-0115

32994182

Stage

Brøsen

Christensen

A comprehensive review of drug-drug interactions with metformin

Clin Pharmacokinet548118242015

10.1007/s40262-015-0270-6

Bian

Jiang

Gan

Zhang

Cai

A glimepiride-metformin multidrug crystal: Synthesis, crystal structure analysis, and physicochemical properties

Molecules2437862019

10.3390/molecules24203786

Scheen

Clinical pharmacokinetics of metformin

Clin Pharmacokinet303593711996

10.2165/00003088-199630050-00003

Palumbo

Metformin: Effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus

J Diabetes Complications121101191998

10.1016/S1056-8727(97)00053-6

9559489

Mbara

Mato

Driver

Nzuza

Mkhombo

Gcwensa

Mcobothi

Owira

Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications

Eur J Pharmacol8981739342021

10.1016/j.ejphar.2021.173934

Notaro

ALG

Neto

FTL

The use of metformin in women with polycystic ovary syndrome: An updated review

J Assist Reprod Genet145735792022

10.1007/s10815-022-02429-9

Cheng

Liu

Fang

Liu

Zhu

Exercise alleviates the apolipoprotein A5-toll-like receptor 4 axis impairment in mice with high-fat diet-induced non-alcoholic steatohepatitis

Front Physiol127833412021

10.3389/fphys.2021.783341

Kalariya

Shoeb

Ansari

Srivastava

Ramana

Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats

Invest Ophthalmol Vis Sci53343134402012

10.1167/iovs.12-9432

Agostini

Masato

Bubacco

Bisaglia

Metformin repurposing for parkinson disease therapy: Opportunities and challenges

Int J Mol Sci233982021

10.3390/ijms23010398

Xiao

Pang

Xue

Wan

Pei

Yan

Metformin restores hippocampal neurogenesis and learning and memory via regulating gut microbiota in the obese mouse model

Brain Behav Immun9568832021

10.1016/j.bbi.2021.02.011

33609653

Kim

Choe

Park

Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease

Korean J Intern Med3713262022

10.3904/kjim.2021.363

34879473

Siskind

Friend

Russell

McGrath

Lim

Patterson

Flaws

Stedman

Moudgil

Sardinha

CoMET: A protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine

BMJ Open8e0210002018

10.1136/bmjopen-2017-021000

29500217

Taylor

Siddiqui

Ambery

Armisen

Challis

Haefliger

Pearson

Doney

ASF

Dillon

Palmer

CNA

Metabolic dysfunction-related liver disease as a risk factor for cancer

BMJ Open Gastroenterol9e0008172022

10.1136/bmjgast-2021-000817

Sousa

Costa

Alves

Soares

Baylina

Fernandes

The impact of metabolic syndrome and type 2 diabetes mellitus on prostate cancer

Front Cell Dev Biol108434582022

10.3389/fcell.2022.843458

Yang

Nishihara

Zhang

Ogino

Qian

Energy sensing pathways: Bridging type 2 diabetes and colorectal cancer?

J Diabetes Complications31122812362017

10.1016/j.jdiacomp.2017.04.012

28465145

Kabat

Kim

Chlebowski

Khandekar

McTiernan

Neuhouser

Parker

Shikany

Stefanick

A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer

Cancer Epidemiol Biomarkers Prev18204620532009

10.1158/1055-9965.EPI-09-0235

19567502

Wang

Ding

The biological and pharmacological connections between diabetes and various types of cancer

Pathol Res Pract2271536412021

10.1016/j.prp.2021.153641

Cook

Cowan

Adipose

StemBookHarvard Stem Cell Institute

Cambridge, MA

2008

Menendez

Vazquez-Martin

Ortega

Fernandez-Real

Fatty acid synthase: Association with insulin resistance, type 2 diabetes, and cancer

Clin Chem554254382009

10.1373/clinchem.2008.115352

19181734

LeRoith

Novosyadlyy

Gallagher

Lann

Vijayakumar

Yakar

Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence

Exp Clin Endocrinol Diabetes116(Suppl 1)S4S62008

10.1055/s-2008-1081488

18777452

Jayalath

Ireland

Fleshner

Hamilton

Jenkins

The relationship between metformin and serum prostate-specific antigen levels

Prostate76144514532016

10.1002/pros.23228

27403913

Park

Hong

Park

Kang

Han

Park

Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study

Metabolism1231548482021

10.1016/j.metabol.2021.154848

34371066

Zhang

AMY

Chu

Daly

Ruiter

Dou

Yang

JCC

de Winter

TJJ

Chhuor

Wang

Flibotte

Effects of hyperinsulinemia on pancreatic cancer development and the immune microenvironment revealed through single-cell transcriptomics

Cancer Metab1052022

10.1186/s40170-022-00282-z

35189981

Koo

McPherson

Hull

Rees

Sharp

Systematic review and meta-analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes

Colorectal Dis13160922022

10.1111/codi.16092

Nayak

Rathore

Bharati

Sahu

Extending the ambit of SGLT2 inhibitors beyond diabetes: A review of clinical and preclinical studies on non-diabetic kidney disease

Expert Rev Clin Pharmacol14151315262021

10.1080/17512433.2021.2028620

Lam

Srivastava

Morvant

Shankar

Srivastava

Association of diabetes mellitus and alcohol abuse with cancer: Molecular mechanisms and clinical significance

Cells1030772021

10.3390/cells10113077

34831299

Srinivasan

Arzoun

Thangaraj

A systematic review: Does insulin resistance affect the risk and survival outcome of breast cancer in women?

Cureus14e217122022

35145826

Lemon

Orr

Modugno

Buckanovich

Coffman

Edwards

Taylor

Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?

Gynecol Oncol16560662022

10.1016/j.ygyno.2022.01.022

Choi

Kikuchi

Gao

Brodzik

Nassour

Yopp

Singal

Zhu

Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling

Nat Commun1014732019

10.1038/s41467-019-09318-3

30931927

Wang

Zhang

Zheng

Kang

Chen

Qin

Zhang

Shao

Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway

Sci Rep753842017

10.1038/s41598-017-05541-4

28710412

Yang

Huang

Zhang

Chen

Han

Zhang

Liu

Metformin antagonizes ovarian cancer cells malignancy through MSLN mediated IL-6/STAT3 signaling

Cell Transplant3096368972110278192021

10.1177/09636897211027819

Rho

Byun

Kim

Lee

Knockdown of LKB1 sensitizes endometrial cancer cells via AMPK activation

Biomol Ther296506572021

10.4062/biomolther.2021.131

Cheng

Wang

Cao

Liu

Gao

Lü

Pan

Metformin inhibits the tumor-promoting effect of low-dose resveratrol, and enhances the anti-tumor activity of high-dose resveratrol by increasing its reducibility in triple negative breast cancer

Free Radic Biol Med1801081202022

10.1016/j.freeradbiomed.2022.01.010

35038549

Eze

Belka

Manapov

Forging a path for metformin use in inoperable locally advanced non-small cell lung cancer

JAMA Oncol7134113422021

10.1001/jamaoncol.2021.2316

Mazurek

Litak

Kamieniak

Kulesza

Jonak

Baj

Grochowski

Metformin as potential therapy for high-grade glioma

Cancers (Basel)122102020

10.3390/cancers12010210

Zhao

Xiao

Zhu

Liu

Zhang

Yang

Niu

Wang

Omentin-1: A newly discovered warrior against metabolic related diseases

Expert Opin Ther Targets102752892022

10.1080/14728222.2022.2037556

Eibl

Rozengurt

Metformin: Review of epidemiology and mechanisms of action in pancreatic cancer

Cancer Metastasis Rev408658782021

10.1007/s10555-021-09977-z

34142285

Wang

Kuhn

Shah

Schmidt

Lam

YWF

MacCarthy

Tenner

Ramirez

Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases

Cancer Med8320632152019

10.1002/cam4.2142

30993905

Erkinantti

Marttila

Sund

Arffman

Urpilainen

Puistola

Hautakoski

Karihtala

Läärä

Jukkola

Association of metformin, other antidiabetic medications, and statins with incidence of colon cancer in patients with type 2 diabetes

Clin Colorectal Cancer20e113e1192021

10.1016/j.clcc.2020.11.003

33279415

Febbraro

Lengyel

Romero

Old drug, new trick: Repurposing metformin for gynecologic cancers?

Gynecol Oncol1356146212014

10.1016/j.ygyno.2014.10.011

Chen

Jia

Tian

Dai

Xie

Tao

Mao

Metformin use is associated with better survival of breast cancer patients with diabetes: A meta-analysis

Oncologist20123612442015

10.1634/theoncologist.2015-0096

Wang

Long

Pan

Mao

Metformin and survival of women with breast cancer: A meta-analysis of randomized controlled trials

J Clin Pharm Ther16135002021

Tseng

Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus

Eur J Cancer50283128372014

10.1016/j.ejca.2014.08.007

25201464

Brancher

Støer

Weiderpass

Damhuis

RAM

Johannesen

Botteri

Strand

Metformin use and lung cancer survival: A population-based study in Norway

Br J Cancer124101810252021

10.1038/s41416-020-01186-9

33262518

Tseng

Metformin reduces thyroid cancer risk in taiwanese patients with type 2 diabetes

PLoS One9e1098522014

10.1371/journal.pone.0109852

25303400

Agrawal

Patel

Agrawal

Makhijani

Markert

Deidrich

Metformin use and the risk of esophageal cancer in Barrett esophagus

South Med J1077747792014

10.14423/SMJ.0000000000000212

25502158

Becker

Jick

Meier

Bodmer

Metformin and the risk of endometrial cancer: A case-control analysis

Gynecol Oncol1295655692013

10.1016/j.ygyno.2013.03.009

Bowker

Majumdar

Veugelers

Johnson

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

Diabetes Care292542582006

10.2337/diacare.29.02.06.dc05-1558

16443869

Gandini

Puntoni

Heckman-Stoddard

Dunn

Ford

DeCensi

Szabo

Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders

Cancer Prev Res (Phila)78678852014

10.1158/1940-6207.CAPR-13-0424

24985407

Zou

Wang

Liu

Metformin induces myeloma cells necrosis and apoptosis and it is considered for therapeutic use

J Chemother151112022

10.1080/1120009X.2022.2062895

Teixeira

Guimarães

IDS

Madeira

Daltoé

Silva

Rangel

Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells

J Bras Pneumol396446492013(In English, Portuguese)

10.1590/S1806-37132013000600002

Lin

Yan

Wen

Metformin induces apoptosis in hepatocellular carcinoma Huh-7 cells in vitro and its mechanism

Zhonghua Zhong Liu Za Zhi357427462013(In Chinese)

Huang

Hong

Wang

Sun

Fang

Xiong

Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis

EBioMedicine611030372020

10.1016/j.ebiom.2020.103037

33039709

Phoenix

Vumbaca

Claffey

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model

Breast Cancer Res Treat1131011112009

10.1007/s10549-008-9916-5

Anisimov

Egormin

Piskunova

Popovich

Tyndyk

Yurova

Zabezhinski

Anikin

Karkach

Romanyukha

Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo

Cell Cycle91881972010

10.4161/cc.9.1.10407

20016287

Memmott

Mercado

Maier

Kawabata

Fox

Dennis

Metformin prevents tobacco carcinogen-induced lung tumorigenesis

Cancer Prev Res (Phila)3106610762010

10.1158/1940-6207.CAPR-10-0055

20810672

Zhang

Lachance

Mattson

Jia

Glucose metabolic crosstalk and regulation in brain function and diseases

Prog Neurobiol2041020892021

10.1016/j.pneurobio.2021.102089

Dai

Wang

Chen

Tsai

Chao

Lin

YAP dictates mitochondrial redox homeostasis to facilitate obesity-associated breast cancer progression

Adv Sci18e21036872022

10.1002/advs.202103687

Fleming

Gonzalez

Petzel

Lin

Morris

Gomez

Lee

Crane

Pisters

PWT

Evans

Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma

Arch Surg1442162212009

10.1001/archsurg.2008.580

19289659

Purcell

Oliveira

CLP

Mackenzie

Robson

Lewis

Prado

Body composition and prostate cancer risk: A systematic review of observational studies

Adv Nutr161532021

10.1093/advances/nmab153

Gong

Wang

Zhang

Sestrin2 as a potential target for regulating metabolic-related diseases

Front Endocrinol (Lausanne)127510202021

10.3389/fendo.2021.751020

34803916

Zell

McLaren

Morgan

Lawson

Rezk

Albers

Chen

Carmichael

Chung

Richmond

A phase IIa trial of metformin for colorectal cancer risk reduction among individuals with history of colorectal adenomas and elevated body mass index

Cancer Prev Res (Phila)132032122020

10.1158/1940-6207.CAPR-18-0262

31818851

Saini

Yang

Metformin as an anti-cancer agent: Actions and mechanisms targeting cancer stem cells

Acta Biochim Biophys Sin (Shanghai)501331432018

10.1093/abbs/gmx106

29342230

Bang

Chen

Ahima

Kim

Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action

Mol Endocrinol28118611932014

10.1210/me.2014-1134

Najafov

Luu

Mookhtiar

Mifflin

Xia

Amin

Ordureau

Wang

Yuan

RIPK1 promotes energy sensing by the mTORC1 pathway

Mol Cell813703852021

10.1016/j.molcel.2020.11.008

Kim

Han

Lee

Park

Chung

Shin

Lee

Metformin enhances the anti-adipogenic effects of atorvastatin via modulation of STAT3 and TGF-β/Smad3 signaling

Biochem Biophys Res Commun4561731782015

10.1016/j.bbrc.2014.11.054

25462562

Lam

Cheng

Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer

Cancer Sci109347134822018

10.1111/cas.13782

Cameron

Logie

Patel

Erhardt

Bacon

Middleton

Harthill

Forteath

Coats

Kerr

Metformin selectively targets redox control of complex I energy transduction

Redox Biol141871972018

10.1016/j.redox.2017.08.018

Feng

Tang

Dong

Zheng

Lin

Huang

Yeung

SCJ

Zhang

Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling

Cell Death Dis5e10882014

10.1038/cddis.2014.59

24577086

Janjetovic

Vucicevic

Misirkic

Vilimanovich

Tovilovic

Zogovic

Nikolic

Jovanovic

Bumbasirevic

Trajkovic

Harhaji-Trajkovic

Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt

Eur J Pharmacol65141502011

10.1016/j.ejphar.2010.11.005

Athreya

Kalari

Cairns

Gaglio

Wills

Niu

Weinshilboum

Iyer

Wang

Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer

Oncotarget827199272152017

10.18632/oncotarget.16109

Yenmiş

Beşli

Saraç

Emre

Şenol

Kanıgür

Metformin promotes apoptosis in primary breast cancer cells by downregulation of cyclin D1 and upregulation of P53 through an AMPK-alpha independent mechanism

Turk J Med Sci518268342021

10.3906/sag-1908-112

Calza

Nyberg

Mäkinen

Soliymani

Cascone

Lindholm

Barborini

Baumann

Lalowski

Eriksson

Lactate-induced glucose output is unchanged by metformin at a therapeutic concentration-a mass spectrometry imaging study of the perfused rat liver

Front Pharmacol91412018

10.3389/fphar.2018.00141

Thakur

Daley

Gaskins

Vasko

Boufraqech

Patel

Sourbier

Reece

Cheng

Kebebew

Metformin targets mitochondrial glycerophosphate dehydrogenase to control rate of oxidative phosphorylation and growth of thyroid cancer in vitro and in vivo

Clin Cancer Res24403040432018

10.1158/1078-0432.CCR-17-3167

29691295

Salani

Marini

Rio

Ravera

Massollo

Orengo

Amaro

Passalacqua

Maffioli

Pfeffer

Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II

Sci Rep320702013

10.1038/srep02070

23797762

Jiang

Song

Qiu

Tian

Wang

Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: A systematic review and meta-analysis

BMJ Open11e0483242021

10.1136/bmjopen-2020-048324

34593492

100

El-Tanani

Al Khatib

Aladwan

Abuelhana

McCarron

Tambuwala

Importance of STAT3 signalling in cancer, metastasis and therapeutic interventions

Cell Signal921102752022

10.1016/j.cellsig.2022.110275

101

Zahra

Afify

Hassan

Nawara

Kumon

Seno

Metformin suppresses self-renewal and stemness of cancer stem cell models derived from pluripotent stem cells

Cell Biochem Funct398969072021

10.1002/cbf.3661

102

Higurashi

Hosono

Takahashi

Komiya

Umezawa

Sakai

Uchiyama

Taniguchi

Hata

Uchiyama

Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: A multicentre double-blind, placebo-controlled, randomised phase 3 trial

Lancet Oncol174754832016

10.1016/S1470-2045(15)00565-3

103

Arrieta

Zatarain-Barrón

Turcott

Barrón

Yendamuri

Cardona

Rosell

Association of BMI with benefit of metformin plus epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma: A secondary analysis of a phase 2 randomized clinical trial

JAMA Oncol84774792022

10.1001/jamaoncol.2021.7015

104

Pusceddu

Vernieri

Di Maio

Prinzi

Torchio

Corti

Coppa

Buzzoni

Bartolomeo

Milione

Impact of diabetes and metformin use on enteropancreatic neuroendocrine tumors: Post hoc analysis of the CLARINET study

Cancers (Basel)14692021

10.3390/cancers14010069

35008233

105

Wang

Lin

Xiong

Wang

Guo

Chen

Wang

Lin

Chen

Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: Results of a phase II clinical trial

Clin Cancer Res26492149322020

10.1158/1078-0432.CCR-20-0113

32646922

106

Maruthur

Tseng

Hutfless

Wilson

Suarez-Cuervo

Berger

Chu

Iyoha

Segal

Bolen

Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis

Ann Intern Med1647407512016

10.7326/M15-2650

27088241

107

Wink

Belderbos

Dieleman

Rossi

Rasch

CRN

Damhuis

RAM

Houben

RMA

Troost

EGC

Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy

Radiother Oncol1184534592016

10.1016/j.radonc.2016.01.012

108

Martin

Hayward

Viros

Marais

Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A

Cancer Discov23443552012

10.1158/2159-8290.CD-11-0280

22576211

Figure 1.

Chemical structure of metformin.

Figure 2.

Multiple functions of metformin. In addition to hypoglycemia, metformin displays antitumor, anti-aging, anti-Parkinson's disease and weight loss effects.

Figure 3.

Anti-neoplastic activity of metformin via inhibition of AMPK/mTOR pathway. Inhibition of AMPK/mTOR pathway leading to the arrest of protein synthesis is a major anti- neoplastic activity of metformin.

Figure 4.

Metformin induces esophageal cancer cell autophagy via the STAT3/Bcl-2/ATG pathway. Metformin inhibits STAT3 expression to decrease Bcl-2 protein expression, which upregulates expression of autophagy marker ATG, thus inducing autophagy to slow tumor growth of esophageal cancer.